Triflusal

Drugs

Volumn 55, Issue 6, 1998, Pages 823-833

  McNeely, W ^a   Goa, K L ^a   De la Cruz, J P ^a   Perez Gomez, E ^a   Aronow, W S ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; TRIFLUSAL;

ARACHIDONIC ACID METABOLISM; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CHEMICAL STRUCTURE; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CORONARY ARTERY BYPASS GRAFT; DEEP VEIN THROMBOSIS; DRUG EFFICACY; EPIGASTRIC PAIN; ERYTHEMA; GRAFT OCCLUSION; HEART INFARCTION; HIP SURGERY; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; META ANALYSIS; NAUSEA; ORAL DRUG ADMINISTRATION; PERIPHERAL VASCULAR DISEASE; PROPHYLAXIS; STOMACH PAIN; STROKE; THROMBOCYTE AGGREGATION INHIBITION; UNSTABLE ANGINA PECTORIS; VOMITING; WALKING;

ANGINA; TRIFLUORO;

EID: 0031807224     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855060-00011     Document Type: Article

References (35)

1. 1. J Hannah WV Ruyle H Jones 1978 Novel analgesic-anti-inflammatory salicylates J Med Chem 21 11 1093 100 309947 10.1021/jm00209a001 1:CAS:528:DyaE1cXlvFSqtLg%3D Hannah J, Ruyle WV, Jones H, et al. Novel analgesic-anti-inflammatory salicylates. J Med Chem 1978 Nov; 21(11): 1093–100
2. 2. M Albors C Castellarnau de L Vila 1987 Inhibition of thromboxane production and platelet function by triflusal in healthy volunteers Revista De Farmacologia Clinica Y Experimental 4 1 11 6 1:CAS:528:DyaL2sXls1yntLY%3D Albors M, de Castellarnau C, Vila L, et al. Inhibition of thromboxane production and platelet function by triflusal in healthy volunteers. Revista De Farmacologia Clinica Y Experimental 1987; 4(1): 11–6
3. 3. JP Cruz De La J Pavia J Garcia-Arnes 1988 Effects of triflusal and acetylsalicylic acid on platelet aggregation in whole blood of diabetic patients Eur J Haematol 40 232 6 2965654 10.1111/j.1600-0609.1988.tb00829.x De La Cruz JP, Pavia J, Garcia-Arnes J, et al. Effects of triflusal and acetylsalicylic acid on platelet aggregation in whole blood of diabetic patients. Eur J Haematol 1988 Mar; 40: 232–6
4. 4. MJ Dominguez M Vacas Y Saez 1985 Effects of triflusal in patients with prosthetic heart valves Clin Ther 7 357 60 3838919 1:STN:280:DyaL2M3gtFGnsA%3D%3D Dominguez MJ, Vacas M, Saez Y, et al. Effects of triflusal in patients with prosthetic heart valves. Clin Ther 1985; 7: 357–60
5. 5. JP Cruz De La JM Mata F Sanchez De La Cuesta 1992 Triflusal versus aspirin on the inhibition of human platelet and vascular cyclooxygenase Gen Pharmacol 23 3 297 300 1639242 De La Cruz JP, Mata JM, Sanchez de La Cuesta F. Triflusal versus aspirin on the inhibition of human platelet and vascular cyclooxygenase. Gen Pharmacol 1992; 23(3): 297–300
6. 6. JP Cruz De La MA Villalobos PJ Garcia 1995 Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers Eur J Clin Pharmacol 47 497 502 10.1007/BF00193701 1:CAS:528:DyaK2MXmtVWnt7g%3D De La Cruz JP, Villalobos MA, Garcia PJ, et al. Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers. Eur J Clin Pharmacol 1995; 47: 497–502
7. 7. JP Cruz De La J Pavia I Bellido 1988 Platelet antiaggregatory effect of triflusal in human whole blood Methods Find Exp Clin Pharmacol 10 273 7 3386335 De La Cruz JP, Pavia J, Bellido I, et al. Platelet antiaggregatory effect of triflusal in human whole blood. Methods Find Exp Clin Pharmacol 1988 Apr; 10: 273–7
8. 8. L Sanchez de Miguel M Prado Sierra del A Lopez Farre 1998 Comparative effects of triflusal and acetylsalicylic acid on nitric oxide generation by human neutrophils Eur J Pharmacol 343 57 65 9551715 10.1016/S0014-2999(97)01518-5 1:CAS:528:DyaK1cXhtlOit7o%3D Sanchez de Miguel L, del Prado Sierra M, Lopez Farre A, et al. Comparative effects of triflusal and acetylsalicylic acid on nitric oxide generation by human neutrophils. Eur J Pharmacol 1998; 343: 57–65
9. 9. Sanchez de Miguel L, Millas I, Garcia Duran M, et al. New mechanisms for the antiaggregating platelet effects of triflusal: role of nitric oxide and neutrophils (abs 241P). Eur Heart J 1997; 18 Abstract supplement: 19
10. 10. J Garcfa-Rafanell JM Planas P Puig-Parellada 1979 Comparison of the inhibitory effects of acetylsalicylic acid and triflusal on enzymes related to thrombosis Arch Int Pharmacodyn Ther 237 2 343 50 Garcfa-Rafanell J, Planas JM, Puig-Parellada P. Comparison of the inhibitory effects of acetylsalicylic acid and triflusal on enzymes related to thrombosis. Arch Int Pharmacodyn Ther 1979 Feb; 237(2): 343–50
11. 11. J Garcfa-Rafanell J Ramis L Gomez 1986 Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets Arch Int Pharmacodyn Ther 284 155 65 Garcfa-Rafanell J, Ramis J, Gomez L, et al. Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets. Arch Int Pharmacodyn Ther 1986 Nov; 284: 155–65
12. 12. L Gomez J Garcfa-Rafanell J Forn 1987 Protective effect of triflusal and acetylsalicylic acid against arachidonic acid induced cerebrovascular occlusion in anaesthetized rats Methods Find Exp Clin Pharmacol 9 13 7 3106730 1:CAS:528:DyaL2sXhvVyksLs%3D Gomez L, Garcfa-Rafanell J, Forn J. Protective effect of triflusal and acetylsalicylic acid against arachidonic acid induced cerebrovascular occlusion in anaesthetized rats. Methods Find Exp Clin Pharmacol 1987 Jan; 9: 13–7
13. 13. M Korves J Cervós-Navarro 1993 Microthrombi formation in focal brain ischemia using Fischer 344 rats: influence of triflusal Methods Find Exp Clin Pharmacol 15 721 7 1:CAS:528:DyaK2cXjtFGntLY%3D Korves M, Cervós-Navarro J. Microthrombi formation in focal brain ischemia using Fischer 344 rats: influence of triflusal. Methods Find Exp Clin Pharmacol 1993 Dec; 15: 721–7
14. 14. N Heye A Campos S Kannuki 1991 Effects of triflusal and acetylsalicylic acid on microthrombi formation in experimental brain ischemia Exp Pathol 41 1 31 6 2022253 10.1016/S0232-1513(11)80043-5 1:CAS:528:DyaK3MXltVGksrs%3D Heye N, Campos A, Kannuki S, et al. Effects of triflusal and acetylsalicylic acid on microthrombi formation in experimental brain ischemia. Exp Pathol 1991; 41(1): 31–6
15. 15. E Ferrari G Reboldi P Marenco 1996 Pharmacokinetic study of triflusal in elderly subjects after single and repeated oral administration Am J Ther 3 630 6 11862303 10.1097/00045391-199609000-00005 Ferrari E, Reboldi G, Marenco P, et al. Pharmacokinetic study of triflusal in elderly subjects after single and repeated oral administration. Am J Ther 1996 Sep; 3: 630–6
16. 16. J Ramis J Torrent R Mis 1990 Pharmacokinetics of triflusal after single and repeated doses in man Int J Clin Pharmacol Ther Toxicol 28 344 9 2272716 1:CAS:528:DyaK3MXpsVGmsA%3D%3D Ramis J, Torrent J, Mis R, et al. Pharmacokinetics of triflusal after single and repeated doses in man. Int J Clin Pharmacol Ther Toxicol 1990 Aug; 28: 344–9
17. 17. J Ramis R Mis J Forn 1991 Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose Eur J Drug Metab Pharmacokinet 16 269 73 1823870 10.1007/BF03189971 1:CAS:528:DyaK38Xktl2ksbw%3D Ramis J, Mis R, Forn J, et al. Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. Eur J Drug Metab Pharmacokinet 1991 Oct–Dec; 16: 269–73
18. 18. L Plaza L López-Bescós L Martín-Jadraque 1993 Protective effect of triflusal against acute myocardial infarction in patients with unstable angina: results of a Spanish multicenter trial Cardiology 82 6 388 98 8402761 10.1159/000175892 1:STN:280:DyaK2c%2Fgs1eqsw%3D%3D Plaza L, López-Bescós L, Martín-Jadraque L. Protective effect of triflusal against acute myocardial infarction in patients with unstable angina: results of a Spanish multicenter trial. Cardiology 1993; 82(6): 388–98
19. 19. F Perez Gomez F Perez Vizcaino A Escriba 1990 Epidemiology of thrombosis and prevention of systemic embolism (I): atrial fibrillation, myocardiopathy, dyskinesia following myocardial infarction Cardiovascular Thrombosis 1–14 5407 Perez Gomez F, Perez Vizcaino F, Escriba A, et al. Epidemiology of thrombosis and prevention of systemic embolism (I): atrial fibrillation, myocardiopathy, dyskinesia following myocardial infarction. In: Perez Gomez F, Roldan I, Lopez Sendon JL, editors. Cardiovascular Thrombosis. Madrid: Fareso, 1990: 1–14. 5407
20. 20. F Perez Gomez F Perez Vizcaino A Escriba 1990 Epidemiology of thrombosis and prevention of systemic embolism (II): mitral valvulopathy and bioprosthesis F Perez Gomez I Roldan JL Lopez-Sendon Cardiovascular Thrombosis Fareso Madrid 15 24 Perez Gomez F, Perez Vizcaino F, Escriba A, et al. Epidemiology of thrombosis and prevention of systemic embolism (II): mitral valvulopathy and bioprosthesis. In: Perez Gomez F, Roldan I, Lopez-Sendon JL, editors. Cardiovascular Thrombosis. Madrid: Fareso, 1990: 15–24
21. 21. A Auteri A Angaroni E Borgatti 1995 Triflusal in the treatment of patients with chronic peripheral arteriopathy: multicentre double-blind clinical study vs placebo Int J Clin Pharmacol Res 15 2 57 63 8593974 1:CAS:528:DyaK2MXpslWisrw%3D Auteri A, Angaroni A, Borgatti E, et al. Triflusal in the treatment of patients with chronic peripheral arteriopathy: multicentre double-blind clinical study vs placebo. Int J Clin Pharmacol Res 1995; 15(2): 57–63
22. 22. J Matias-Guiu J Alvarez-Sabin A Codina 1997 Estudio comparativo del efecto del ácido acetilsalicílco en dosis bajas y el triflusal en la pravención de eventos cardiovasculares en adultos jóvenes con enfermedad cerebrvascular isquémica Rev Neural 25 147 1669 72 1:STN:280:DyaK1c7ksFGjug%3D%3D Matias-Guiu J, Alvarez-Sabin J, Codina A. Estudio comparativo del efecto del ácido acetilsalicílco en dosis bajas y el triflusal en la pravención de eventos cardiovasculares en adultos jóvenes con enfermedad cerebrvascular isquémica. Rev Neural 1997; 25(147): 1669–72
23. 23. J Matias-Guiu J Alvarez L Galiano 1994 The efficacy and safety of low-dose aspirin versus triflusal in the long-term outcome of young stroke patients [abstract] Neurology 44 2 288 10.1212/WNL.44.2.288 Matias-Guiu J, Alvarez J, Galiano L, et al. The efficacy and safety of low-dose aspirin versus triflusal in the long-term outcome of young stroke patients [abstract]. Neurology 1994 Apr; 44 Suppl. 2: 288
24. 24. S Smirne L Ferini-Strambi D Cucinotta 1994 Triflusal and prevention of cerebrovascular attacks: double-blind clinical study vs ASA (abs. 53) J Neurology 241 1 S130 Smirne S, Ferini-Strambi L, Cucinotta D, et al. Triflusal and prevention of cerebrovascular attacks: double-blind clinical study vs ASA (abs. 53). J Neurology 1994 Jun; 241 Suppl. 1: S130
25. 25. S Lopez-Pousa J Mercadal-Dalmau AM Marti-Cuadrso 1997 Triflusal en la prevención de la demencia vascular Rev Neurol 25 1525 8 9462972 1:STN:280:DyaK1c%2FktFahtQ%3D%3D Lopez-Pousa S, Mercadal-Dalmau J, Marti-Cuadrso AM, et al. Triflusal en la prevención de la demencia vascular. Rev Neurol 1997; 25: 1525–8
26. 26. P Guiteras J Altimiras A Aris 1989 Prevention of aortocoronary vein-graft attrition with low-dose aspirin and triflusal, both associated with dipyridamole: a randomized, double-blind, placebo-controlled trial Eur Heart J 10 159 67 2647494 10.1093/eurheartj/10.suppl_G.42 1:STN:280:DyaL1M7ntVOkuw%3D%3D Guiteras P, Altimiras J, Aris A, et al. Prevention of aortocoronary vein-graft attrition with low-dose aspirin and triflusal, both associated with dipyridamole: a randomized, double-blind, placebo-controlled trial. Eur Heart J 1989 Feb; 10: 159–67
27. 27. M Masotti A Tura C Crexells 1991 Antiplatelet agents and their effect on complications during or soon after percutaneous transluminal coronary angioplasty J Int Med Res 19 414 8 1748235 1:STN:280:DyaK38%2FosVSnsA%3D%3D Masotti M, Tura A, Crexells C, et al. Antiplatelet agents and their effect on complications during or soon after percutaneous transluminal coronary angioplasty. J Int Med Res 1991 Sep–Oct; 19: 414–8
28. 28. Putz P, Buyse H, Delvaux D, et al. Triflusal versus acetylsalicylic acid — a double-blind study for the prophylaxis of deep vein thrombosis after hip surgery. Acta Chir Belg 1991 Nov–Dec: 269–76
29. 29. M Monreal E Lafoz J Roca 1995 Platelet count, antiplatelet therapy and pulmonary embolism — a prospective study in patients with hip surgery Thromb Haemostasis 73 380 5 1:CAS:528:DyaK2MXksVersLY%3D Monreal M, Lafoz E, Roca J, et al. Platelet count, antiplatelet therapy and pulmonary embolism — a prospective study in patients with hip surgery. Thromb Haemostasis 1995 Mar; 73: 380–5
30. 30. E Esmatjes M Maseras M Gallego 1989 Effect of treatment with an inhibitor of platelet aggregation on the evolution of background retinopathy: 2 years of follow-up Diabetes Res Clin Pract 7 285 91 2693031 10.1016/0168-8227(89)90017-X 1:STN:280:DyaK3c7is1aksw%3D%3D Esmatjes E, Maseras M, Gallego M, et al. Effect of treatment with an inhibitor of platelet aggregation on the evolution of background retinopathy: 2 years of follow-up. Diabetes Res Clin Pract 1989 Nov 6; 7: 285–91
31. 31. E Esmatjes JI Conget J Gaya 1990 Effects of thromboxane synthesis inhibitor triflusal on renal hemodynamics in microalbuminuric diabetic patients Diabetes Care 13 1114 7 2261825 10.2337/diacare.13.11.1114 1:STN:280:DyaK3M%2FosFehug%3D%3D Esmatjes E, Conget JI, Gaya J, et al. Effects of thromboxane synthesis inhibitor triflusal on renal hemodynamics in microalbuminuric diabetic patients. Diabetes Care 1990 Nov; 13: 1114–7
32. 32. Triflusal versus aspirin for the prevention of infarction: a randomized stroke study (TAPIRSS). Stroke 1997 Feb; 28(2): 478
33. 33. Triflusal versus acetylsalicylic acid in secondary prevention of cerebral infarction: TACIP study (Triflusal, Aspirin, Cerebral Infarction Prevention). Stroke 1997 Feb; 28(2): 478
34. 34. Cruz-Fernandez JM, Lopez V, Cabades A, et al. Triflusal vs aspirin in the acute phase of myocardial infarction: the TIM study main results. Presented at the European Society of Cardiology Congress Vienna; August 22–26 1998
35. 35. López-Bescós L, Kalmeller C, Cruz-Fernandez JM, et al. Incidence of haemorrhagic stroke in fibrinolytic treated patients after acute myocardial infarction. TIM study: a subgroup. Presented at the European Society of Cardiology Congress Vienna; August 22–26 1998